Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Director Declaration

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director Declaration

4 May 2018 12:00

RNS Number : 1832N
AstraZeneca PLC
04 May 2018
 

4 May 2018 12:00 BST

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Sheri McCoy, a Non-Executive Director of the Company, was appointed as a director of Stryker Corporation following the conclusion of its Annual Meeting of Shareholders with effect from 2 May 2018.

 

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

Investor Relations

Thomas Kudsk Larsen

 

 

+44 203 749 5712

Craig Marks

Finance; Fixed Income; M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

US toll free

+1 866 381 7277

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNBZLFBVEFFBBL
12345678910
Date   Source Headline
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:05 amRNSSubcutaneous Saphnelo approved in EU
16th Dec 20257:00 amRNSEnhertu approved in US for 1L HER2+ metastatic BC
4th Dec 20253:00 pmRNSHolding(s) in Company
1st Dec 20253:05 pmRNSBlock listing Interim Review
1st Dec 20253:00 pmRNSTotal Voting Rights
26th Nov 20257:00 amRNSImfinzi approved in US for early gastric cancer
24th Nov 20257:00 amRNSAstraZeneca manufacturing investment in Maryland
20th Nov 20257:00 amRNSKoselugo (selumetinib) approved in the US
17th Nov 20253:00 pmRNSHolding(s) in Company
14th Nov 202511:00 amRNSDirector/PDMR Shareholding
10th Nov 20253:00 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNS9M and Q3 2025 results
3rd Nov 20254:00 pmRNSResult of General Meeting
3rd Nov 20253:00 pmRNSTotal Voting Rights
28th Oct 20257:05 amRNSDirector Declaration
28th Oct 20257:00 amRNSKoselugo (selumetinib) approved in the EU
22nd Oct 20257:00 amRNSTezspire Approved in EU for CRSwNP
20th Oct 20257:05 amRNSUS FDA Approves Tezspire in CRSwNP
20th Oct 20257:00 amRNSPositive CHMP opinion for subcutaneous Saphnelo
13th Oct 20257:00 amRNSAgreement with US Govt to lower medicine prices
7th Oct 20257:00 amRNSBaxdrostat met primary endpoint in Bax24 Ph3 trial
6th Oct 20257:30 amRNSDatroway improved OS and PFS in TROPION-Breast02
1st Oct 20253:00 pmRNSTotal Voting Rights
29th Sep 20257:30 amRNSEnhertu improved IDFS in early BC in DB-05
29th Sep 20257:00 amRNSAZN harmonises listing structure
25th Sep 20254:30 pmRNSDirector/PDMR Shareholding
22nd Sep 20257:05 amRNSKoselugo recommended for EU approval
22nd Sep 20257:00 amRNSTezspire Recommended for Approval in EU for CRSwNP
17th Sep 20257:05 amRNSSaphnelo met primary endpoint in TULIP-SC
17th Sep 20257:00 amRNSUpdate on RESOLUTE Phase III trial
1st Sep 20253:00 pmRNSTotal Voting Rights
28th Aug 20253:00 pmRNSHolding(s) in Company
26th Aug 20253:00 pmRNSHolding(s) in Company
21st Aug 20253:00 pmRNSHolding(s) in Company
18th Aug 20253:00 pmRNSDirector/PDMR Shareholding
15th Aug 20253:00 pmRNSHolding(s) in Company
12th Aug 20253:00 pmRNSHolding(s) in Company
1st Aug 20253:00 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSH1 and Q2 2025 results
24th Jul 20257:00 amRNSGefurulimab nanobody met Phase III endpoints
22nd Jul 20257:00 amRNSAstraZeneca plans to invest $50bn in the US
16th Jul 20257:00 amRNSUpdate on anselamimab in AL amyloidosis
14th Jul 20257:00 amRNSBaxdrostat met primary endpt in BaxHTN PhIII trial
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
BRWM
BlackRock World Mining Trust plc
LSE
-5.88%
ALAI
ALAI.L
LSE
0.00%
LWI
Lowland Inv.
LSE
-0.58%
PREM
Premier African Minerals
LSE
9.52%
MTO
Mitie
LSE
-3.06%
Trending
ITM
Itm Power
LSE
-10.85%
PPP
Pennpetro Energy
LSE
0.00%
GST
GSTechnologies
LSE
8.11%
NANO
Nanoco
LSE
-10.69%
EZJ
easyJet
LSE
0.34%